Developer of biopharmaceuticals engaged in the discovery, development, and commercialization of new drugs and therapies for difficult to treat illnesses. The company offers Reslizumab for eosinophilic inflammatory conditions. It also provides Anti-TNF, a class of small molecule anti-TNF receptor agents with the potential to be orally administered. The companies portfolio includes treatments for central nervous system disorders, pain and cancer and include eight proprietary products in the United States, along with more than 100 products internationally. Cephalon's research pipeline is focused on developing new compounds and new indications for existing products, while their business collaborations capitalize on new products and smart drug delivery technologies.